Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs

Friday, November 10, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Nov. 9, 2017 /PRNewswire/ -- Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs

Download the full report: https://www.reportbuyer.com/product/5190776

SummaryOphthalmology is a therapy area that encompasses the diagnosis, treatment and prevention of diseases associated with the eyes and the visual

system. The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. In 2015, it was estimated that over 3 million Americans suffer from visual impairment, defined as having 20/40 vision or worse after best possible correction. A person with 20/40 vision is able to read letters from 20 feet away that an individual with ''normal'' 20/20 vision could read from 40 feet, so a person that can still not perform this after best possible intervention with glasses or contact lenses is classed as being visually impaired.

Ophthalmology pipeline has a highly active deals landscape. There were 271 licensing deals and 152 co-development deals completed between 2006 and 2016 across the therapy area, of which 94 licensing deals and 33 co-development deals had a disclosed value. Many products in the ophthalmology pipeline have previously been involved in licensing and co-development deals. Most of these are in the Preclinical stage of development, although many deals also took place for products at Phase II.

The pipeline contains a diverse range of molecular targets, and no single target dominates by any clear margin. However, products acting on components of the immune system - largely cytokines and cytokine receptors - and its regulatory signaling pathways make up the largest segment, followed by angiogenesis inhibitors. Generally, the composition by molecular target across the pipeline suggests that product development is shifting away from the type of therapies that currently dominate the market, indicating that the available therapeutic options could diversify.

The report "Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs" assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products. In-depth analysis reveals that the level of innovation within the therapy area pipeline is high, with strong potential for drugs to address unmet needs and be commercially lucrative.

Scope- The pipeline is large, with 865 products in active development. Does current pipeline innovation hold the potential to affect the future ophthalmology market?- There are 194 first-in-class products in the ophthalmologic disorder pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?- Analysis of strategic consolidations and deals revealed a high level of activity in recent years for licensing agreements, but a low level of co-development. How do deal frequency and value compare between molecular targets and molecule types, and which first-in-class targets have not yet been involved in deals?

Reasons to buy- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.- Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.- Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.- Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Download the full report: https://www.reportbuyer.com/product/5190776

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com

 

View original content:http://www.prnewswire.com/news-releases/frontier-pharma-ophthalmology-therapeutics---gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs-300553579.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store